These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15758699)

  • 41. Early prostate cancer diagnosis and therapy.
    Glodé LM
    Adv Intern Med; 2000; 45():41-64. PubMed ID: 10635045
    [No Abstract]   [Full Text] [Related]  

  • 42. [Consensus conference. The detection of localized cancer of the prostate. Paris, 8-9 December 1989].
    Ann Urol (Paris); 1990; 24(1):5-8. PubMed ID: 1690964
    [No Abstract]   [Full Text] [Related]  

  • 43. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].
    Damber JE
    Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209
    [No Abstract]   [Full Text] [Related]  

  • 49. Lack of progress in early diagnosis of bladder cancer.
    Araki M; Nieder AM; Manoharan M; Yang Y; Soloway MS
    Urology; 2007 Feb; 69(2):270-4. PubMed ID: 17320662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract]   [Full Text] [Related]  

  • 52. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 53. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 54. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].
    Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E
    Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292
    [No Abstract]   [Full Text] [Related]  

  • 55. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 56. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.
    Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323
    [No Abstract]   [Full Text] [Related]  

  • 57. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate cancer--more information and more questions.
    Dall'Era M; Carroll PR
    J Urol; 2007 May; 177(5):1607-8. PubMed ID: 17437768
    [No Abstract]   [Full Text] [Related]  

  • 59. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
    Carlucci JR; Nabizada-Pace F; Samadi DB
    Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer screening: is it possible to explain diametrically opposed views?
    Richardson A
    N Z Med J; 2005 Feb; 118(1209):U1289. PubMed ID: 15711622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.